Amsbio offers a growing list of experimental cell lines, recombinant proteins, and screening services to help accelerate the development of new CAR-T cell therapies.
Personalized treatment for cancer reached a new milestone in 2017 with the FDA approval of CAR-T cell therapy for treatment of children and adolescents with B cell acute lymphoblastic leukemia (ALL).
Amsbio Business Development Manager – Dr Maja Petkovic commented “The first FDA approved treatments were CAR-T cells directed against the B cell protein CD19. This success inspired new research that demonstrated CAR-T cell therapy targeting multiple B cell proteins offers improved cancer treatment by reducing tumor recurrence from antigen escape, enhancing anti-tumor efficacy through synergistic recognition, overcoming tumor heterogeneity, and potentially improving treatment specificity.”
Dr Petkovic added “Our ready-to-use CAR-T cell line portfolio is extensive and growing. It includes knockout cell lines for TCR, B2M, and CIITA, enabling the modelling of universal CAR-T cells. We can also provide sterile, pathogen- and mycoplasma-free cell lines expressing common CAR targets like BCMA, CD19, CD20, CD22 and more, many of which include the luciferase reporter for simple monitoring. Amsbio now can also offer ready-to-use CAR-expressing cells for assay design/optimization and as positive controls in co-culture assays, as well as bispecific CAR T cells targeting CD19 & CD22.
For further information ready-to-use sterile cell lines for CAR-T therapy research please visit https://www.amsbio.com/car-t-cell-research/ or contact Amsbio on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / info@amsbio.com.
